|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Hematology/Oncology Unit, Massachusetts
General Hospital, Harvard Medical School, Boston, MA; and the Centre
for Child Health Research, The University of Western Australia and
Western Australian Institute for Medical Research, Perth, Western
Australia.
Thrombocytopenia is a common medical problem for which the
main treatment is platelet transfusion. Given the increasing use of
platelets and the declining donor population, identification of a safe
and effective platelet growth factor could improve the management of
thrombocytopenia. Thrombopoietin (TPO), the c-Mpl ligand, is the
primary physiologic regulator of megakaryocyte and platelet
development. Since the purification of TPO in 1994, 2 recombinant forms
of the c-Mpl ligand Thrombocytopenia is a common problem in the
management of patients with cancer and other conditions that affect
hematopoietic cells. Thrombocytopenia may be occasionally encountered
with conventional chemotherapy regimens used to treat solid tumors but
can be a major clinical problem in the management of patients receiving dose-intensive chemotherapy, induction and consolidation therapy for
leukemia, palliative chemotherapy following multiple previous regimens,
and multiple cycles of certain chemotherapeutic regimens.1 Multiagent regimens such as MAID (mesna, adriamycin, ifosfamide, and
dacarbazine) and ICE (ifosfamide, carboplatin, and etoposide) used in
the treatment of lymphoma, sarcoma, breast, ovarian, and germ cell
tumors often produce thrombocytopenia that requires dose modifications,
platelet transfusions, or both to prevent bleeding
complications.1,2 Thrombocytopenia associated with the use
of newer chemotherapy agents such as gemcitabine may limit their use in
patients with lung, breast, or ovarian cancer. Additionally, patients
with associated bone marrow failure have a higher risk of severe
thrombocytopenia and bleeding complications with any chemotherapy regimen.
Thrombocytopenia is also a frequent problem in the management of
nonchemotherapy patients with myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), chronic liver
disease, and acquired immunodeficiency syndrome (AIDS).3-6
The chronic thrombocytopenia observed in these conditions results from
defective or diminished platelet production or enhanced immunologic and nonimmunologic platelet destruction and may be associated with abnormal
platelet function.3-6 Furthermore, patients undergoing liver transplantation, cardiovascular surgery, requiring intra-aortic balloon counterpulsation, or receiving supportive intensive care often
experience severe, acute thrombocytopenia that is associated with
increased mortality.7,8
Platelet transfusion therapy is currently the only acute
treatment for severe thrombocytopenia. Although temporarily effective in controlling severe thrombocytopenia, platelet transfusion therapy is
associated with several problems, including refractoriness and
alloimmunization, transmission of infectious agents, and transfusion reactions.9-15 The limited supply of blood products can
also be problematic. The use of dose-intensive chemotherapy regimens
and hematopoietic progenitor cell transplantation, as well as intensive support for the medical and surgical patient, has resulted in an
increasing demand for platelet products; this demand is likely to
escalate in an attempt to improve clinical outcomes for oncology and
nononcology patients. The limitations of platelet transfusions and the
increased costs associated with the complications of such transfusions
have prompted a search for growth factors that stimulate platelet
production, thereby reducing or eliminating the need for platelet
transfusions.1,2
Over the past 2 decades, a number of hematopoietic growth
factors with thrombopoietic activity have been identified, including recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF); stem cell factor (c-kit ligand or steel factor); interleukin 1 (IL-1),
IL-3, IL-6, and IL-11; and thrombopoietin (TPO).16-26
Early clinical studies of many of these cytokines, including IL-1,
IL-3, IL-6, and IL-11, showed their ability to stimulate platelet
production directly or indirectly in patients with chemotherapy-induced
thrombocytopenia.27-32 In phase 1 studies,
administration of IL-1 Although ILs stimulate thrombopoiesis, their action on platelets is not
their principal physiologic function. Recently, gene-targeting studies
have shown that the primary physiologic function of IL-11 is to
maintain female fertility; it is not essential for hematopoiesis either
in normal physiology or in response to hematopoietic
stress.34,35 Furthermore, the pleiotropic effect of ILs
often results in unwanted or unacceptable toxic effects, including
hyperbilirubinemia, rapid induction of anemia, fever, fatigue, chills,
hypotension, and headache.27,32,36-38 Although
administration of IL-11 reduces the need for platelet transfusions by
approximately a third in patients with severe chemotherapy-induced
thrombocytopenia, it is associated with mild peripheral edema, dyspnea,
conjunctival redness, and a low incidence of atrial arrhythmias and
syncope.30,33 Thus, despite the ability of ILs to
ameliorate thrombocytopenia in a subset of patients treated with
conventional chemotherapy, the moderate toxicity encountered with IL
treatment may interfere with its therapeutic effect and potential use
as a thrombopoietic agent.
In contrast to ILs, TPO, also known as c-Mpl ligand, is a relatively
lineage-specific cytokine that stimulates megakaryocyte growth and
maturation in vitro and is a potent in vivo thrombopoietic growth
factor. Gene-targeting studies have established that TPO is the most
important physiologic regulator of steady-state megakaryocyte and
platelet production.39-41 Cloning of the c-Mpl ligand led
to the clinical development of various preparations of TPO, including recombinant human thrombopoietin (rhTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). This
article presents an overview of the biology of the recombinant thrombopoietins, the results of all phase 1 and 2 clinical studies of
different preparations of TPO, and the problems encountered in their development.
Isolation of c-Mpl ligand
Structure and biologic properties of TPO
TPO levels usually increase in response to the decline in platelet mass
and remain elevated during persistent thrombocytopenia. Although
hepatic transcription and translation of the TPO gene appears to be
constant,49,50 most studies indicate that the circulating
platelet mass directly determines the circulating level of
TPO.20,51-56 Transfusion of platelets into
thrombocytopenic animals or humans has resulted in a decrease in plasma
TPO levels20,52-54,57 and similar results have been
observed when normal platelets are transfused into c-Mpl-deficient
mice.51 These findings indicate that TPO is constitutively
synthesized in the liver and removed from circulation by binding to the
c-Mpl receptor on platelets and possibly bone marrow megakaryocytes.
Some investigators have alternatively suggested that local production
of TPO by bone marrow stromal cells is increased during thrombocytopenia and stimulates megakaryocyte growth.58
Direct evidence to support the relative contribution of this mechanism to platelet production is lacking; but in experiments in which livers
from TPO As predicted, TPO increases the size, ploidy, and number of
megakaryocytes and stimulates the expression of platelet-specific markers.20,62,63 In addition to acting as a potent
megakaryocyte colony-stimulating factor, TPO has a synergistic effect
on the growth of myeloid and erythroid precursors when combined with other hematopoietic growth factors such as erythropoietin or stem cell
factor.64-66 The role of TPO as the principal physiologic regulator of platelet production has been confirmed in studies of
mutant mice lacking the ability to produce either TPO
(TPO TPO and its receptor also have a major effect on production of
primitive pluripotent stem cells and progenitor cells from other
lineages. Despite normal red and white blood cell numbers, mice
deficient in TPO (TPO Despite its activity on hematopoietic stem cells and early
megakaryocytopoiesis, TPO has little effect on platelets and on the
late stages of megakaryocyte development.74-77 This
contrasts with granulocyte colony-stimulating factor (G-CSF) and
GM-CSF, for which an action on late myeloid precursor cells and mature myeloid cells is well established.78,79 Perhaps the most
significant consequence of TPO's minimal effect on late-stage
megakaryocytes is the inability of TPO to hasten platelet shedding from
megakaryocytes. In fact, if anything, TPO inhibits platelet
shedding.74
Although TPO does not directly cause platelet activation, at
pharmacologically high doses it does have a modest effect on mature
platelets by increasing their reactivity to some aggregation stimuli;
TPO-treated platelets require half as much adenosine diphosphate for a
response.80,81 Other hematopoietic growth factors also
reduce the threshold for platelet activation but the clinical relevance
is uncertain. This effect may be mediated by TPO-dependent activation
of phosphatidylinositide 3-kinase, which in turn phosphorylates
Thr306 and Ser473 of platelet protein kinase
B Recombinant TPO
In healthy animals, TPO exerts its peripheral blood effects exclusively on platelets; with no increase in white or red blood cells. Administration of either form of recombinant TPO to healthy nonhuman primates results in a dose-dependent increase in megakaryocyte number, size, and ploidy and up to a 5-fold increase in circulating platelet counts.89 There is a requisite lag time of 4 to 5 days before the platelet count rises; this reflects the finding that TPO acts primarily on early, not late, precursor cells. In murine models of severe chemotherapy- or radiation-induced thrombocytopenia or both, daily administration of recombinant TPO increases megakaryocyte numbers in the bone marrow, ameliorates the depth and duration of thrombocytopenia, and reduces the severity of leukopenia and anemia.86,90 Similar results have been observed with recombinant TPO in nonhuman primate models of chemotherapy- and radiation-induced thrombocytopenia.91-93 In addition to these recombinant forms of TPO, several other molecules that bind and activate c-Mpl are being tested. One of these molecules is a fusion protein of TPO and IL-3. Administration of this molecule has been shown to increase platelet count in animals, but it has been found to be immunogenic and is no longer under development.94 Recently, great interest has been focused on the development of TPO peptide95 and nonpeptide96 mimetics. These mimetics are designed to bind to the TPO receptor but have no sequence homology with endogenous TPO. Finally, a TPO receptor "potentiating" peptide has been developed that binds to c-Mpl at a location distant from the TPO binding area and prevents receptor internalization after TPO binding, thereby increasing TPO action. An analogous peptide that binds the erythropoietin receptor and potentiates erythropoietin has also recently been described.97
Nonmyeloablative treatments The stimulatory effects of PEG-rHuMGDF and rhTPO on megakaryocyte and platelet production have been demonstrated in several clinical trials (Table 2).98-107 PEG-rHuMGDF, the most widely studied recombinant TPO, has produced dose-dependent increases in platelet counts in patients with advanced malignancies and attenuated chemotherapy-induced thrombocytopenia in randomized, placebo-controlled clinical trials.98,99,105-107 When administered before chemotherapy as a daily subcutaneous injection, PEG-rHuMGDF produced a dose-dependent increase in peripheral blood platelet counts and a modest increase in megakaryocyte, erythroid, and myeloid progenitor cell levels in patients with advanced cancer.99 No evidence of platelet activation or altered platelet function was observed with PEG-rHuMGDF administration.108
Subsequent trials evaluated the effects of PEG-rHuMGDF on hematologic recovery after chemotherapy. A randomized, placebo-controlled, dose-escalation study evaluated the effects of PEG-rHuMGDF after carboplatin-paclitaxel chemotherapy in 53 patients with lung cancer.98 Patients treated with PEG-rHuMGDF after chemotherapy had a higher median nadir platelet count (188 × 109/L) than did placebo-treated patients (111 × 109/L) and also showed more rapid recovery of platelet counts (14 days versus > 21 days). The need for platelet transfusions was unaffected because the chemotherapy regimen used did not frequently generate severe thrombocytopenia. In another randomized study of 41 patients with advanced cancer undergoing chemotherapy with carboplatin and cyclophosphamide, treatment with PEG-rHuMGDF enhanced platelet recovery in a dose-related manner.99 Although the platelet nadir occurred earlier in the PEG-rHuMGDF-treated group, its depth was unchanged. Similar results were observed in a dose-scheduling trial of PEG-rHuMGDF with G-CSF carried out in patients with non-small-cell lung cancer treated with carboplatin-paclitaxel.100 PEG-rHuMGDF-treated patients had a higher platelet nadir than did placebo-treated patients (89 × 109/L versus 27 × 109/L in cycle 1). Moreover, the need for transfusion was lower in the PEG-rHuMGDF group than in the placebo group (17% versus 64% in the first 2 cycles). However, in the later cycles, thrombocytopenia became dose limiting in all treatment groups. A recent study examined the efficacy of different doses and schedules of PEG-rHuMGDF in 68 patients with advanced cancer.106 Patients received 1 cycle of carboplatin and cyclophosphamide and were then randomly assigned to receive PEG-rHuMGDF or placebo after the second and subsequent cycles of carboplatin and cyclophosphamide chemotherapy. The platelet nadir was higher and the duration of grade 3 or 4 thrombocytopenia shorter when PEG-rHuMGDF was administered to patients who received the same dose of chemotherapy for at least 2 cycles. No evidence of an effect on platelet nadir was observed when PEG-rHuMGDF was given before chemotherapy. Unlike in animal chemotherapy models (in which multilineage responses are often seen), no effect of recombinant TPOs on red or white blood cell recovery has been seen in humans. rhTPO has also produced a dose-dependent increase in
platelet counts in patients with sarcomas and gynecologic
malignancies.101-104,109 A phase 1 and 2 study examined the effect of rhTPO on megakaryocyte and platelet
production before and after chemotherapy with doxorubicin and
ifosfamide in patients with sarcomas who were at high risk of
developing chemotherapy-induced thrombocytopenia. When given intravenously before chemotherapy, a single dose of rhTPO was associated with a dose-dependent increase in peripheral platelets that
began on day 4 and peaked on day 12 in most patients.102 This increase in platelet number was accompanied by a 4-fold increase in bone marrow megakaryocytes and a marked expansion and mobilization of erythroid, myeloid, and megakaryocyte progenitor cells. A single dose of rhTPO given intravenously after chemotherapy with doxorubicin and ifosfamide decreased the incidence of thrombocytopenia in some
patients.101 A second trial investigated the clinical
safety and activity of rhTPO administered subcutaneously to previously treated patients with gynecologic malignancies before and after chemotherapy with carboplatin.104 As observed in the
previous study, administration of a single subcutaneous dose of rhTPO
before chemotherapy produced a modest dose-dependent rise in
circulating platelet counts. Administration of multiple doses of rhTPO
after carboplatin chemotherapy produced an earlier platelet count nadir but effectively reduced the depth of the platelet nadir and the duration of severe thrombocytopenia (Figure
3). The need for platelet transfusions
decreased by 75% (Figure
4).104
Myeloablative treatments Prolonged and severe chemotherapy-induced thrombocytopenia is a major cause of morbidity in patients receiving intensive chemotherapy for acute leukemia and those undergoing blood stem cell transplantation.110,111 In recent years, several studies have evaluated the safety and efficacy of PEG-rHuMGDF and rhTPO in the management of thrombocytopenia associated with chemotherapy for acute leukemia and stem cell transplantation (Tables 3 and 4).112-125
In contrast to their effect in the nonmyeloablative setting, PEG-rHuMGDF and rhTPO have not had a clinically significant effect on platelet production when administered to patients receiving dose-intensive therapy for acute leukemia and those undergoing stem cell transplantation after chemotherapy. Moderate increase in peak platelet counts and reduction in time to full platelet recovery were often achieved in patients treated with PEG-rHuMGDF and rhTPO. However, no improvement in time to recovery to a platelet count more than or equal to 20 × 109/L and no reduction in the need for platelet transfusions were observed in these studies.112-114,119,120 In preclinical studies, treatment with TPO before bone marrow harvesting accelerated platelet reconstitution in recipient mice after transplantation, suggesting that this approach may be effective in shortening the time to platelet independence after stem cell transplantation.126 With this approach, one study showed that administration of rhTPO to patients during mobilization of peripheral blood progenitor cells increased CD34+ yield before stem cell transplantation. Small, statistically significant improvements in neutrophil recovery and platelet and erythrocyte transfusion requirements were noted after transplantation.121 MDS Hematopoietic growth factors have had some success in ameliorating the neutropenia and anemia associated with myelodysplastic syndrome (MDS). The recombinant TPOs may have a similar benefit: some in vitro studies have shown that bone marrow cells of patients with MDS can differentiate into the megakaryocytic lineage when exposed to recombinant TPO.127,128 Because of the underlying heterogeneity of MDS, some individuals might have responsive marrow whereas others might not. Endogenous TPO levels are normal to slightly elevated in MDS,129 so whether they can help predict responsiveness to exogenous TPO requires further investigation. In a preliminary report, various intravenous doses of PEG-rHuMGDF were given daily for 14 days to 21 Japanese patients with MDS (refractory anemia and refractory anemia with ringed sideroblasts) with platelet counts less than 30 × 109/L. The peak effect of PEG-rHuMGDF occurred 5 to 6 weeks later with an average doubling of platelet count; responses were seen in a third of the patients, and a multilineage effect was observed in a few patients.130Human immunodeficiency virus Several studies have examined thrombocytopenia in patients or primates infected with human immunodeficiency virus (HIV) with respect to peripheral platelet mass turnover, marrow megakaryocytopoiesis, and endogenous TPO levels.3,131,132 A 10-fold disparity between the reduced platelet production and expanded megakaryocyte mass was observed in the bone marrow of HIV patients with thrombocytopenia.132 This suggests that, despite the expanded megakaryocyte mass, HIV-infected megakaryocytes have a high rate of apoptosis and resultant ineffective thrombopoiesis and thrombocytopenia. Harker and colleagues131 showed that, in thrombocytopenic chimpanzees infected with HIV, administration of PEG-rHuMGDF rapidly eliminated thrombocytopenia. With normal or slightly elevated endogenous TPO levels in 6 HIV-infected patients, platelet counts in all patients increased 10-fold within 14 days of the start of PEG-rHuMGDF treatment.132 This increase was not associated with change in the megakaryocyte mass, platelet life span, or viral load. What appeared to occur was an increase in the rate of effective platelet production from the bone marrow megakaryocytes of these individuals. These data suggest that, in HIV-related immune thrombocytopenic purpura, TPO can be expected to produce clinically beneficial increases in platelet counts.A similar response has been recently seen in 3 of 4 Japanese patients with non-HIV-related ITP treated with intravenous PEG-rHuMGDF.133 One patient with ITP has been successfully treated twice weekly with subcutaneous PEG-rHuMGDF for over 3 years.134 Liver disease Recent understanding of TPO biology suggests that reduced hepatic production of TPO may play a major role in thrombocytopenia associated with liver disease. TPO is produced primarily in the liver, and thrombocytopenia in animals seems to be proportional to the extent of liver resection.135 In addition, after transplantation of healthy livers into TPO / mice, platelet counts returned
toward normal, suggesting that the majority of TPO is produced in the
liver.59 An association between low platelet counts
(median, 84 × 109/L; range,
26 × 109/L-112 × 109/L) and low levels of
TPO (median, < 20 pg/mL; range, < 20-182 pg/mL) has been reported in
patients before orthotopic liver transplantation.60,61 Within 4 days of orthotopic liver transplantation, TPO levels rose
above normal and were accompanied by increased amounts of reticulated
platelets. At 14 days after transplantation, platelet counts were
normal in 14 of 18 patients (median, 254 × 109/L; range,
70 × 109/L-398 × 109/L) and TPO levels
returned to normal in 14 of 18 patients (median, 59 pg/mL; range, < 20-639 pg/mL). No appreciable change in spleen size was observed. In
multivariate analysis, the increase in TPO was the only variable that
correlated with the increase in platelet count. Thus, TPO could
potentially be used to reduce hemorrhage in patients with
thrombocytopenia due to liver disease or to prepare such patients for
liver transplantation.
Surgery Approximately 40% of all platelet transfusions are used in surgical settings.136 Preoperative and postoperative thrombocytopenia complicates surgical procedures and mandates platelet transfusions. No clinical studies have targeted this important area. However, in dogs, the administration of PEG-rHuMGDF 4 days before surgery decreased thrombocytopenia after cardiopulmonary bypass.137 Despite its 5-day lag time before platelet rise, judicial administration of TPO before surgery may ameliorate preoperative and postoperative thrombocytopenia and reduce the need for platelet transfusions.Transfusion medicine The striking effect of TPO on the mobilization of CD34+ cells and expansion of multilineage stem cell progenitor pools in vivo led to an evaluation of its activity in 3 areas: mobilization of peripheral blood stem cells before stem cell transplantation, ex vivo expansion of pluripotent stem cells from umbilical cord blood or bone marrow, and increase in the yield of platelet apheresis from healthy donors.Stem cell mobilization.
Recently, several pilot studies evaluated the activity of various doses
and schedules of rhTPO or PEG-rHuMGDF in combination with G-CSF and
chemotherapy as part of a mobilization regimen for stem cell
transplantation (Table 4).99,121-123,138,139 In contrast to peak progenitor cell numbers on days 5 to 7 usually obtained with
G-CSF alone, a peak on days 12 to 15 was produced by the combination of
PEG-rHuMGDF and G-CSF. However, since a full pharmacodynamic response
profile to PEG-rHuMGDF was not performed in this study, the exact day
of peak stem cell mobilization was not determined. The addition of
rhTPO to G-CSF for chemotherapy mobilization regimens substantially
increased CD34+ yields (Figure
5). The promising results observed in
these early studies were recently confirmed in a large randomized phase
2 study of rhTPO in patients undergoing high-dose chemotherapy and transplantation of peripheral blood stem cells (Table
4).121 Treatment with rhTPO in various doses and schedules
reduced the number of aphereses needed to reach a target graft (ie,
CD34+ > 5 × 106/kg) and, compared with
placebo treatment, increased the percentage of patients reaching a
target graft (from 46% in the placebo group to 79% in the rhTPO
group), as well as the percentage of patients reaching the minimum
target graft (ie, CD34+ > 2 × 106/kg)
(from 75% in the placebo group to 94% in the rhTPO group). These
studies demonstrate the ability of rhTPO to mobilize CD34+
cells safely and effectively and increase the harvest of
CD34+ cells used for stem cell transplantation.
Ex vivo expansion of primitive stem cells.
The role of TPO in the expansion and prolonged survival of primitive
stem cells derived from bone marrow or umbilical cord blood has been
the focus of several recent investigations. Yagi and
colleagues140 demonstrated that administration of TPO
alone can sustain ex vivo expansion of hematopoietic stem cells in
long-term bone marrow cultures (LTBMCs) from mice (Figure
6). The continuous presence of TPO
resulted in the generation of long- and short-term colony-forming cells
and maintained the relative amount of high-proliferative-potential colony-forming cells (Figure 7). Most
important, competitive repopulation studies found that the TPO-treated
LTBMC cells were as effective as fresh marrow. Subsequent data from
this research group suggest that the expanded population of stem cells,
when transplanted into recipient mice, is adequate for the long-term
repopulation.
Piacibello and colleagues141 showed that the use of growth factors could expand human cord blood CD34+ cells ex vivo by many million-fold in total number; the CD34+ component and the lineage-specific progenitors increased proportionately. Although TPO alone and Flt 3 ligand alone were insufficient in stimulating sustained growth, a combination of the 2 growth factors accounted for this rapid increase in cell number during 24 weeks in culture. However, whether the expanded cell population can be used clinically for transplantation has not been demonstrated. Platelet apheresis.
Extensive studies have shown that healthy apheresis donors maximally
increase their platelet count 10 to 14 days after a single injection of
PEG-rHuMGDF.136,142,143 The rise in platelet count is dose
dependent and leads directly to an increase in the apheresis platelet
yield (Figure 8). The platelets collected
have normal aggregation responses and normal function on transfusion
into thrombocytopenic recipients. Transfusions with the higher platelet doses extended the duration of transfusion independence and possibly reduced bleeding episodes when compared with standard doses. The corrected count increment was also improved when patients were transfused with platelets mobilized by PEG-rHuMGDF rather than with
those harvested from control donors.
Radioprotection Although there are no studies in humans, the potential for TPO to function as a radioprotectant is another area of clinical interest. In mice, administration of TPO 2 hours after exposure to sublethal total body irradiation (TBI) dramatically ameliorates the thrombocytopenia that is seen at day 10 in these mice.144 Mice treated with rhTPO before irradiation have a higher platelet count nadir (739 × 109/L) than do those that are untreated before irradiation (144 × 109/L); unirradiated control mice had a platelet count of 1123 × 109/L. This protective effect was enhanced when rhTPO was administered close to TBI. Stem cells appeared to be highly sensitive to the effects of rhTPO, possibly because it prevented apoptosis when given from 2 hours before until 2 hours after TBI. This very narrow window of protection underscores the importance of the timing of the administration of rhTPO vis-à-vis the irradiation. Furthermore, red and white blood cell counts also appeared to be protected somewhat by the administration of rhTPO close to the time of TBI (Figure 9).144 These results suggest a major radioprotective effect of rhTPO on progenitor cells in the bone marrow. This finding is in line with previous data suggesting that pluripotential stem cells are sensitive to the presence of TPO and that TPO can support their survival.145,146 Similar results have been noted in subsequent studies that investigated the effect of rhTPO in mice exposed to lethal doses of TBI.147 Almost all the mice that received rhTPO close to the time of irradiation survived, whereas all the mice that received placebo died within 30 days of receiving TBI. Furthermore, recovery of blood counts in all lineages improved in those mice that received rhTPO within several hours of TBI.
Whether these results can be expanded to the chemotherapy setting has not been fully explored. Conceivably the antiapoptotic effects of TPO might lessen chemotherapy-induced apoptosis of pluripotential stem cells and thereby ameliorate the pancytopenia of chemotherapy. Safety of recombinant TPO In most of the studies with TPO in myeloablative and nonmyeloablative chemotherapy, patients also received myeloid growth factors. Although interactions of TPO with myeloid growth factors had been seen in one animal model,148 none have been noted an any clinical study.Administration of multiple doses of PEG-rHuMGDF to some cancer patients and healthy volunteers was associated with an abrogation of its pharmacologic effect as a result of the development of neutralizing antibodies.85,100,149,150 These antibodies neutralized both the recombinant and endogenous TPO, resulting in thrombocytopenia. Thrombocytopenia occurred in 4 of 665 cancer/stem cell transplantation/leukemia patients given multiple doses and in 2 (1.2%) of 210 healthy volunteers who received 2 doses and in 11 (8.9%) of 124 healthy volunteers given 3 doses of PEG-rHuMGDF.85,149 No subject developed neutralizing antibodies or thrombocytopenia after a single injection. Evaluation of these thrombocytopenic subjects showed that the thrombocytopenia was due to the formation of an IgG antibody to PEG-rHuMGDF that cross-reacted with endogenous TPO and neutralized its biologic activity.85,149,150 In 2 patients, thrombocytopenia was associated with anemia and neutropenia, suggesting an effect on a stem cell population.85,150 Because endogenous TPO is produced in a constitutive fashion by the liver, thrombocytopenia ensues. PEG-rHuMGDF was withdrawn from clinical trials in the United States by Amgen in September 1998 because of this side effect.151 A possible explanation for the immunogenicity of PEG-rHuMGDF administration may be that this molecule is truncated, nonglycosylated, and pegylated, in contrast to the full-length, glycosylated rhTPO molecule (Table 1). In addition, PEG-rHuMGDF has usually been administered subcutaneously, whereas full-length native rhTPO has been injected intravenously. Because TPO is a potent mobilizer of dendritic cells, injection of any form of TPO subcutaneously might enhance its immunogenicity. Support for this latter hypothesis comes from recent experiments in which PEG-ratMGDF was injected into rats once monthly for 3 months by either a subcutaneous or intravenous route. Most animals treated subcutaneously developed neutralizing antibodies and thrombocytopenia whereas those treated intravenously did not (personal communication, Dr A. Shimosaka, April 2002). To date, the development of neutralizing antibodies in patients treated with intravenous rhTPO has not been reported, although one nonneutralizing antibody was found after subcutaneous injection of rhTPO.102,104
The development of recombinant TPO has led to a wide number of discoveries describing the underlying biology of platelet production in normal and pathologic settings. Recombinant TPO has demonstrated a unique pharmacology, unlike other hematopoietic growth factors. Both rhTPO and PEG-rHuMGDF have a prolonged half-life of about 40 hours, and thus continuous dosing with TPO does not seem to be required; one or more appropriately timed doses may even be superior to multiple doses. TPO does not increase the platelet count for 5 days and has its peak effect 10 to 12 days later. It has little effect on mature megakaryocytes and may actually inhibit their shedding of platelets. TPO is the most specific and effective growth factor identified to date for the prevention and treatment of thrombocytopenia. Preliminary clinical evidence indicates that TPO administration may be a helpful adjunct to the conventional approach of platelet transfusion therapy for some cancer patients with chemotherapy-induced thrombocytopenia. However, the studies with TPO, as with IL-11, mostly involved nonconventional chemotherapy regimens that caused considerable thrombocytopenia. For most routine chemotherapy regimens, clinically significant thrombocytopenia is relatively uncommon. The overall impact of TPO on the need for platelet transfusions will probably not be great, especially with the recent reduction in the threshold "trigger" for platelet transfusions to 10 × 109/L.152-154 The failure to find any biologic effect in myeloablative regimens is still surprising given the success of the myeloid growth factors in these same settings. This is probably not simply due to inadequate dosing schemes; many have been tried. Rather it may reflect aspects of the clinical biology of TPO that are not yet recognized. The elevated endogenous TPO concentration in all of these settings may have already saturated the TPO receptor or, alternatively, may even prevent platelet shedding.155 The ultimate clinical indications for recombinant TPO or TPO mimetics will certainly depend on the results of continuing and future studies. Further studies to elucidate their complex and unique biology will help to determine their optimal application in the treatment of thrombocytopenia. While the potential of TPO to reduce the extent of chemotherapy-induced thrombocytopenia and reduce the need for platelet transfusions in the nonmyeloablative chemotherapy setting may be enhanced with innovative dosing schemes, TPO will probably have its greatest impact in nononcology settings such as the stimulation of directed platelet apheresis donors. The thrombocytopenia associated with HIV infection, ITP, MDS, liver disease, radiation, surgery, and intensive care patients accounts for over half of all platelet transfusions136 and remains in need of an effective thrombopoietic growth factor.
Submitted November 8, 2001; accepted July 24, 2002.
Supported in part by grants from the National Institutes of Health HL54838 and HL61272 (D.J.K.), the National Institutes of Health, Medical Research Council, Canberra, Australia; Amgen Inc, Thousand Oaks, CA (C.G.B.); and Pharmacia Inc, Peapack, NJ (D.J.K., C.G.B.).
D.J.K. has been a consultant for and received research support from Amgen Inc, Kirin Inc, and Pharmacia Inc. C.G.B. was a consultant to Amgen Inc during the course of the clinical studies with PEG-rHuMGDF.
Reprints: David J. Kuter, Hematology/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, 100 Blossom St, Boston, MA 02114; e-mail: kuter.david{at}mgh.harvard.edu.
1. Kaushansky K. The thrombocytopenia of cancer: prospects for effective cytokine therapy. Hematol Oncol Clin North Am. 1996;10:431-455[CrossRef][Medline] [Order article via Infotrieve]. 2. Prow D, Vadhan-Raj S. Thrombopoietin: biology and potential clinical applications. Oncology (Huntingt). 1998;12:1597-1604[Medline] [Order article via Infotrieve]1607-1598; discussion 1611-1594. 3. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327:1779-1784[Abstract]. 4. Mittelman M, Zeidman A. Platelet function in the myelodysplastic syndromes. Int J Hematol. 2000;71:95-98[Medline] [Order article via Infotrieve]. 5. Lazarus AH, Ellis J, Semple JW, Mody M, Crow AR, Freedman J. Comparison of platelet immunity in patients with SLE and with ITP. Transfus Sci. 2000;22:19-27[CrossRef][Medline] [Order article via Infotrieve]. 6. Lawrence SP, Lezotte DC, Durham JD, Kumpe DA, Everson GT, Bilir BM. Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS): a retrospective analysis. Dig Dis Sci. 1995;40:1575-1580[CrossRef][Medline] [Order article via Infotrieve]. 7. Alvarez JM, Gates R, Rowe D, Brady PW. Complications from intra-aortic balloon counterpulsation: a review of 303 cardiac surgical patients. Eur J Cardiothorac Surg. 1992;6:530-535[Abstract]. 8. Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med. 1998;105:27-32[CrossRef][Medline] [Order article via Infotrieve]. 9. Chiu EK, Yuen KY, Lie AK, et al. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion. 1994;34:950-954[CrossRef][Medline] [Order article via Infotrieve]. 10. Davda RK, Collins KA, Kitchens CS. Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion. Am J Med Sci. 1994;307:340-341[Medline] [Order article via Infotrieve]. 11. Chambers LA, Kruskall MS, Pacini DG, Donovan LM. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion. 1990;30:219-221[CrossRef][Medline] [Order article via Infotrieve]. 12. Contreras M. Diagnosis and treatment of patients refractory to platelet transfusions. Blood Rev. 1998;12:215-221[CrossRef][Medline] [Order article via Infotrieve]. 13. Engelfriet CP, Reesink HW, Aster RH, et al. Management of alloimmunized, refractory patients in need of platelet transfusions. Vox Sang. 1997;73:191-198[CrossRef][Medline] [Order article via Infotrieve]. 14. Friedberg RC, Mintz PD. Causes of refractoriness to platelet transfusion. Curr Opin Hematol. 1995;2:493-498[Medline] [Order article via Infotrieve]. 15. Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang. 1999;76:1-13[CrossRef][Medline] [Order article via Infotrieve].
16.
Kimura H, Ishibashi T, Shikama Y, et al.
Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6.
Blood.
1990;76:2493-2500 17. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124[CrossRef][Medline] [Order article via Infotrieve]. 18. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-568[CrossRef][Medline] [Order article via Infotrieve]. 19. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-538[CrossRef][Medline] [Order article via Infotrieve].
20.
Kuter DJ, Beeler DL, Rosenberg RD.
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.
Proc Natl Acad Sci U S A.
1994;91:11104-11108
21.
Kato T, Ogami K, Shimada Y, et al.
Purification and characterization of thrombopoietin.
J Biochem.
1995;118:229-236 22. Metcalf D, Burgess AW, Johnson GR, et al. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol. 1986;128:421-431[CrossRef][Medline] [Order article via Infotrieve].
23.
Debili N, Masse JM, Katz A, Guichard J, Breton-Gorius J, Vainchenker W.
Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells.
Blood.
1993;82:84-95
24.
Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ.
Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin.
Blood.
1994;83:1499-1506 25. Metcalf D, Begley CG, Williamson DJ, et al. Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp Hematol. 1987;15:1-9[Medline] [Order article via Infotrieve].
26.
Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ.
Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice.
Blood.
1986;68:46-57 27. Vadhan-Raj S, Kudelka AP, Garrison L, et al. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994;12:707-714[Abstract]. 28. Leonardi V, Danova M, Fincato G, Palmeri S. Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia. Oncol Rep. 1998;5:1459-1464[Medline] [Order article via Infotrieve].
29.
D'Hondt V, Humblet Y, Guillaume T, et al.
Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.
Blood.
1995;85:2347-2353
30.
Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al.
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
Blood.
1996;87:3615-3624
31.
Tepler I, Elias L, Smith JW, et al.
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
Blood.
1996;87:3607-3614
32.
Smith JWD, Longo DL, Alvord WG, et al.
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
N Engl J Med.
1993;328:756-761 33. Vredenburgh JJ, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant. 1998;4:134-141[Medline] [Order article via Infotrieve].
34.
Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley GC.
Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis.
Blood.
1997;90:2148-2159 35. Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med. 1998;4:303-308[CrossRef][Medline] [Order article via Infotrieve].
36.
Gordon MS, Nemunaitis J, Hoffman R, et al.
A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Blood.
1995;85:3066-3076 37. Lazarus HM, Winton EF, Williams SF, et al. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant. 1995;15:935-942[Medline] [Order article via Infotrieve].
38.
Nieken J, Mulder NH, Buter J, et al.
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.
Blood.
1995;86:900-905
39.
Carver-Moore K, Broxmeyer HE, Luoh SM, et al.
Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice.
Blood.
1996;88:803-808
40.
Gainsford T, Roberts AW, Kimura S, et al.
Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production.
Blood.
1998;91:2745-2752
41.
Gainsford T, Nandurkar H, Metcalf D, Robb L, Begley CG, Alexander WS.
The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor.
Blood.
2000;95:528-534 42. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol. 1958;20:350-355[Medline] [Order article via Infotrieve]. 43. Wendling F, Tambourin P. The oncogene V-MPL, a putative truncated cytokine receptor which immortalized hemtopoietic progenitors. Nouv Rev Fr Hematol. 1991;33:145-146[Medline] [Order article via Infotrieve].
44.
Vigon I, Mornon JP, Cocault L, et al.
Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.
Proc Natl Acad Sci U S A.
1992;89:5640-5644
45.
Methia N, Louache F, Vainchenker W, Wendling F.
Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.
Blood.
1993;82:1395-1401 46. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Letters. 1994;353:57-61[CrossRef][Medline] [Order article via Infotrieve]. 47. Foster D, Hunt P. The biological significance of truncated and full-length forms of Mpl ligand. In: Kuter DJ,Hunt P,Sheridan W,Zucker-Franklin D, eds. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, NJ: Humana Press; 1997:203-214.
48.
Foster DC, Sprecher CA, Grant FJ, et al.
Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization.
Proc Natl Acad Sci U S A.
1994;91:13023-13027 49. Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999;105:478-485[CrossRef][Medline] [Order article via Infotrieve].
50.
Stoffel R, Wiestner A, Skoda RC.
Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.
Blood.
1996;87:567-573
51.
Fielder PJ, Gurney AL, Stefanich E, et al.
Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets.
Blood.
1996;87:2154-2161
52.
Kuter DJ, Rosenberg RD.
Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit.
Blood.
1994;84:1464-1472
53.
Kuter DJ, Rosenberg RD.
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.
Blood.
1995;85:2720-2730 54. Kuter DJ. The physiology of platelet production. Stem Cells. 1996;14:88-101[Medline] [Order article via Infotrieve]. 55. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345-356[CrossRef][Medline] [Order article via Infotrieve].
56.
Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K.
Human platelets display high-affinity receptors for thrombopoietin.
Blood.
1997;89:1896-1904 57. Scheding S, Bergmann M, Shimosaka A, et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion. 2002;42:321-327[CrossRef][Medline] [Order article via Infotrieve].
58.
Sungaran R, Markovic B, Chong BH.
Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization.
Blood.
1997;89:101-107
59.
Quin S, Fu F, Li W, Chen Q, de Sauvage FJ.
Primary role of the liver in thrombopoietin production shown by tissue-specific knockout.
Blood.
1998;92:2189-2191 60. Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol. 1997;27:127-131[CrossRef][Medline] [Order article via Infotrieve].
61.
Peck-Radosavljevic M, Wichlas M, Zacherl J, et al.
Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production.
Blood.
2000;95:795-801 62. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-571[CrossRef][Medline] [Order article via Infotrieve].
63.
Broudy VC, Lin NL, Kaushansky K.
Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.
Blood.
1995;85:1719-1726
64.
Rasko JE, O'Flaherty E, Begley CG.
Mpl ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors.
Stem Cells.
1997;15:33-42
65.
Ku H, Yonemura Y, Kaushansky K, Ogawa M.
Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.
Blood.
1996;87:4544-4551
66.
Sitnicka E, Lin N, Priestley GV, et al.
The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.
Blood.
1996;87:4998-5005
67.
de Sauvage FJ, Carver-Moore K, Luoh SM, et al.
Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.
J Exp Med.
1996;183:651-656 68. de Sauvage FJ, Villeval JL, Shivdasani RA. Regulation of megakaryocytopoiesis and platelet production: lessons from animal models. J Lab Clin Med. 1998;131:496-501[CrossRef][Medline] [Order article via Infotrieve]. 69. Alexander WS, Roberts AW, Maurer AB, Nicola NA, Dunn AR, Metcalf D. Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. Stem Cells. 1996;14:124-132[Abstract].
70.
Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D.
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.
Blood.
1996;87:2162-2170
71.
Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW.
Thrombocytopenia in c-mpl-deficient mice.
Science.
1994;265:1445-1447 72. Scott CL, Robb L, Mansfield R, Alexander WS, Begley CG. Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice. Exp Hematol. 2000;28:1001-1007[CrossRef][Medline] [Order article via Infotrieve].
73.
Kimura S, Roberts AW, Metcalf D, Alexander WS.
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin.
Proc Natl Acad Sci U S A.
1998;95:1195-1200 74. Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol. 1996;95:227-233[Medline] [Order article via Infotrieve]. 75. Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost. 1995;74:1541-1545[Medline] [Order article via Infotrieve]. 76. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 1995;374:48-52[CrossRef][Medline] [Order article via Infotrieve]. 77. Li J, Kuter DJ. The end is just the beginning: megakaryocyte apoptosis and platelet release. Int J Hematol. 2001;74:365-374[Medline] [Order article via Infotrieve].
78.
Begley CG, Lopez AF, Nicola NA, et al.
Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors.
Blood.
1986;68:162-166 79. Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest. 1986;78:1220-1228[Medline] [Order article via Infotrieve].
80.
Peng J, Friese P, Wolf RF, et al.
Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs.
Blood.
1996;87:4158-4163
81.
Harker LA, Hunt P, Marzec UM, et al.
Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.
Blood.
1996;87:1833-1844
82.
Kroner C, Eybrechts K, Akkerman JW.
Dual regulation of platelet protein kinase B.
J Biol Chem.
2000;275:27790-27798 83. Snyder E, Perrotta P, Rinder H, Baril L, Nichol J, Gilligan D. Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion. Transfusion. 1999;39:258-264[CrossRef][Medline] [Order article via Infotrieve]. 84. Xia Y, Li J, Bertino A, Kuter DJ. Thrombopoietin and the TPO receptor during platelet storage. Transfusion. 2000;40:976-987[CrossRef][Medline] [Order article via Infotrieve].
85.
Li J, Yang C, Xia Y, et al.
Thrombocytopenia caused by the development of antibodies to thrombopoietin.
Blood.
2001;98:3241-3248
86.
Hokom MM, Lacey D, Kinstler OB, et al.
Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice.
Blood.
1995;86:4486-4492 87. Sheridan WP, Kuter DJ. Mechanism of action and clinical trials of Mpl ligand. Curr Opin Hematol. 1997;4:312-316[Medline] [Order article via Infotrieve]. 88. Begley CG, Basser RL. Biologic and structural differences of thrombopoietic growth factors. Semin Hematol. 2000;37:19-27[Medline] [Order article via Infotrieve].
89.
Harker LA, Marzec UM, Hunt P, et al.
Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Blood.
1996;88:511-521
90.
Ulich TR, del Castillo J, Yin S, et al.
Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice.
Blood.
1995;86:971-976
91.
Harker LA, Marzec UM, Kelly AB, et al.
Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Blood.
1997;89:155-165 92. Akahori H, Shibuya K, Obuchi M, et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol. 1996;94:722-728[CrossRef][Medline] [Order article via Infotrieve].
93.
Neelis KJ, Hartong SC, Egeland T, Thomas GR, Eaton DL, Wagemaker G.
The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony- stimulating factor in myelosuppressed rhesus monkeys.
Blood.
1997;90:2565-2573 94. Giri JG, Smith WG, Kahn LE, et al. Promegapoietin, a chimeric growth factor for megakaryocyte and platelet restoration [abstract]. Blood. 1997;90:580a.
95.
Cwirla SE, Balasubramanian P, Duffin DJ, et al.
Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.
Science.
1997;276:1696-1699 96. Erickson-Miller CL, Delorme E, Tian SS, et al. Discovery and characterization of a selective, non-peptidyl thrombopoietin receptor agonist [abstract]. Blood. 2000;96:675a.
97.
Naranda T, Wong K, Kaufman RI, Goldstein A, Olsson L.
Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site.
Proc Natl Acad Sci U S A.
1999;96:7569-7574
98.
Fanucchi M, Glaspy J, Crawford J, et al.
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
N Engl J Med.
1997;336:404-409
99.
Basser RL, Rasko JE, Clarke K, et al.
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Blood.
1997;89:3118-3128 100. Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-HUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy [abstract]. Proceedings ASCO. 1998;17:73a. 101. Vadhan-Raj S, Patel S, Broxmeyer HE, et al. Phase I-II investigtion of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract]. Blood. 1996;88:448a.
102.
Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al.
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.
Ann Int Med.
1997;126:673-681 103. Vadhan-Raj S, Verschraegen C, McGarry L, et al. Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecological malignancy [abstract]. Blood. 1997;90:580a.
104.
Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al.
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Ann Intern Med.
2000;132:364-368 105. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279-1281[CrossRef][Medline] [Order article via Infotrieve].
106.
Basser RL, Underhill C, Davis I, et al.
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
J Clin Oncol.
2000;18:2852-2861 107. Moskowitz C, Nimer S, Gabrilove J, et al. A randomized, double blind, placebo-controlled, dose finding, efficacy and safety study of PEG-rHuMGDF (M) in non-Hodgkin's lymphoma (NHL) patients (pts) treated with ICE (ifosfamide, carboplatin and etoposide) [abstract]. J Clin Oncol. 1998;17:76a.
108.
O'Malley CJ, Rasko JE, Basser RL, et al.
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
Blood.
1996;88:3288-3298 109. Vadhan-Raj S, Patel S, Broxmeyer H, et al. Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract]. J Clin Oncol. 1999;18:52a. 110. Tornebohm E, Lockner D, Paul C. A retrospective analysis of bleeding complications in 438 patients with acute leukaemia during the years 1972-1991. Eur J Haematol. 1993;50:160-167[Medline] [Order article via Infotrieve]. 111. Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996;10:600-608[Medline] [Order article via Infotrieve].
112.
Archimbaud E, Ottmann OG, Yin JA, et al.
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
Blood.
1999;94:3694-3701 113. Archimbaud E, Ottmann O, Lin J, et al. A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia (AML): early results [abstract]. Blood. 1996;99:447a.
114.
Schiffer CA, Miller K, Larson RA, et al.
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
Blood.
2000;95:2530-2535 115. Cripe L, Neuberg D, Tallman M, et al. A pilot study of recombinant human thrombopoietin (rh-TPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AML) [abstract]. Blood. 1998;92:616a. 116. Glaspy J, Vredenburgh J, Demetri GD, et al. Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support [abstract]. Blood. 1997;90:580a. 117. Bolwell B, Vredenburgh J, Overmoyer B, et al. Safety and biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous peripheral blood progenitor cell transplantation (PBPC) [abstract]. Blood. 1997;90:171a. 118. Beveridge R, Schuste RM, Waller E, et al. Randomized, double-blind, placebo-controlled trial of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous bone marrow transplantation [abstract]. Blood. 1997;90:580a. 119. Nash R, Kurzrock R, DiPersio J, et al. Safety and activity of recombinant human thrombopoietin (rhTPO) in patients (pts) with delayed platelet recovery (DPR) [abstract]. Blood. 1997;90:262a. 120. Nash RA, Kurzrock R, DiPersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25-34[CrossRef][Medline] [Order article via Infotrieve].
121.
Somlo G, Sniecinski I, ter Veer A, et al.
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Blood.
1999;93:2798-2806 122. Gajewski J, Korbling M, Donato M, et al. Recombinant human thrombopoietin (rhTPO) for mobilization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancer: preliminary results of a phase I trial [abstract]. Blood. 1997;90:97a. 123. Linker C, Anderlini P, Herzig R, et al. A randomized, placebo-controlled, phase II trial of recombinant human thrombopoietin (rhTPO) in subjects undergoing high dose chemotherapy (HDC) and PBPC transplant [abstract]. Blood. 1998;92:682a. 124. Linker C. Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantation. Semin Hematol. 2000;37:35-40[Medline] [Order article via Infotrieve]. 125. Bolwell B, Vredenburgh J, Overmoyer B, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000;26:141-145[CrossRef][Medline] [Order article via Infotrieve].
126.
Fibbe WE, Heemskerk DP, Laterveer L, et al.
Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice.
Blood.
1995;86:3308-3313 127. Liu Yin JA, Adams JA, Brereton ML, Hann A, Harrison BD, Briggs M. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors. Br J Haematol. 2000;108:743-746[CrossRef][Medline] [Order article via Infotrieve]. 128. Fontenay-Roupie M, Dupont JM, Picard F, et al. Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res. 1998;22:527-535[CrossRef][Medline] [Order article via Infotrieve]. 129. Nichol JL. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol. 1998;5:203-208[Medline] [Order article via Infotrieve]. 130. Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) [abstract]. Blood. 2000;96:296a.
131.
Harker LA, Marzec UM, Novembre F, et al.
Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
Blood.
1998;91:4427-4433 132. Harker LA, Carter RA, Marzec UM, et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy [abstract]. Blood. 1998;92(suppl 1):707a. 133. Dan K, Nomura S, Hotta T, Fujimura K, Ikeda Y. Biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-MGDF) in patients with idiopathic thrombocytopenic purpura [abstract]. Blood. 2001;98:299a. 134. Rice L, Nichol JL, Delavari M, Roskos L, Bacille MH, McMillan R. Cyclic thrombocytopenia with platelet auto-antibodies: response to PEG-rHu megakaryocyte growth and development factor [abstract]. Blood. 1998;92:180b. 135. Siemensma NP, Bathal PS, Penington DG. The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med. 1975;86:817-833[Medline] [Order article via Infotrieve]. 136. Kuter DJ. The use of PEG-rhuMGDF in platelet apheresis. Stem Cells. 1998;16:231-242[Medline] [Order article via Infotrieve].
137.
Nakamura M, Toombs CF, Duarte IG, et al.
Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
Ann Thorac Surg.
1998;66:1216-1223 138. Rasko JE, Basser RL, Boyd J, et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol. 1997;97:871-880[CrossRef][Medline] [Order article via Infotrieve]. 139. Murray LJ, Luens KM, Estrada MF, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol. 1998;26:207-216[Medline] [Order article via Infotrieve].
140.
Yagi M, Ritchie KA, Sitnicka E, Storey C, Roth GJ, Bartelmez S.
Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin.
Proc Natl Acad Sci U S A.
1999;96:8126-8131
141.
Piacibello W, Sanavio F, Garetto L, et al.
Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood.
Blood.
1997;89:2644-2653
142.
Kuter DJ, Goodnough LT, Romo J, et al.
Thrombopoietin therapy increases platelet yields in healthy platelet donors.
Blood.
2001;98:1339-1345
143.
Goodnough LT, Kuter DJ, McCullough J, et al.
Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
Blood.
2001;98:1346-1351
144.
Neelis KJ, Visser TP, Dimjati W, et al.
A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells.
Blood.
1998;92:1586-1597 145. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol. 1996;24:265-269[Medline] [Order article via Infotrieve]. 146. Kaushansky K. Thrombopoietin: more than a lineage-specific megakaryocyte growth factor. Stem Cells. 1997;15(suppl 1):97-103[Medline] [Order article via Infotrieve]. 147. Mouthon MA, Van der Meeren A, Gaugler MH, et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys. 1999;43:867-875[CrossRef][Medline] [Order article via Infotrieve].
148.
Molineux G, Hartley C, McElroy P, McCrea C, Kerzic P, McNiece I.
An analysis of the effects of combined treatment with rmGM-CSF and PEG- rHuMGDF in murine bone marrow transplant recipients.
Stem Cells.
1997;15:43-49 149. Yang C, Xia Y, Li J, Kuter DJ. The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF [abstract]. Blood. 1999;94:681a.
150.
Basser RL, O'Flaherty E, Green M, et al.
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.
Blood.
2002;99:2599-2602 151. F-D-C Reports. In Brief: Amgen Megagen. The Pink Sheet. 1998;60:27.
152.
Rebulla P, Finazzi G, Marangoni F, et al.
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia.
N Engl J Med.
1997;337:1870-1875 153. Rebulla P. Trigger for platelet transfusion. Vox Sang. 2000;78(suppl 2):179-182[Medline] [Order article via Infotrieve].
154.
Wandt H, Frank M, Ehninger G, et al.
Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
Blood.
1998;91:3601-3606 155. Kuter DJ. Whatever happened to thrombopoietin? Transfusion. 2002;42:279-283[CrossRef][Medline] [Order article via Infotrieve].   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
recombinant human thrombopoietin (rhTPO) and
pegylated recombinant human megakaryocyte growth and development factor
(PEG-rHuMGDF)
before or after carboplatin therapy increased
platelet counts and was effective at attenuating thrombocytopenia
associated with chemotherapy.
